ULSS3 SERENISSIMA - Ospedale dell'Angelo di Mestre

10 trials 5 recruiting

10 Registered trials

5 Currently recruiting

Organisation

ULSS3 SERENISSIMA - Ospedale dell'Angelo di Mestre

Location

Italy

Identifier

ORL-000003223

Address

via Paccagnella 11, Italy

Departments

DIPARTIMENTO DI ONCOLOGIA
EMATOLOGIA
ONCOLOGIA
Oncologia Medica
UO EMATOLOGIA

Clinical trials at this site (10)

Search interface

Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending

2024-518617-25-00 newly diagnosed non-M3 FLT3-positive acute myeloid leuk 4
Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting

2024-512696-12-00 BCR-ABL1+ Chronic Myeloid Leukemia 4 2025-06-24
The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k… Recruiting

2023-510240-20-00 Adult Philadelphia Chromosome-Negative Acute Lymphoblas 4 2022-10-05
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting

2023-505901-17-00 Acute Myeloid Leukemia (LMA) with FLT3 mutation 5 2020-04-24
Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting

2023-510516-39-00 Acute B-cell Lymphoblastic Leukemia with minimal residu 4 2019-10-30
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Very High-Risk T-Lineage Acute Lymphoblastic Leukemia ( 4 2024-10-17
Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi… Ended

2023-510432-36-00 Acute Myeloid Leukemia with NPM1 mutation 4 2022-03-01
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended

2024-516868-28-00 Ph+ Acute Lymphoblastic Leukemia 4 2021-05-04